Christian B. Voigtlander Sells 5,555 Shares of ICU Medical, Inc. (NASDAQ:ICUI) Stock

ICU Medical, Inc. (NASDAQ:ICUIGet Free Report) COO Christian B. Voigtlander sold 5,555 shares of the company’s stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $135.55, for a total value of $752,980.25. Following the completion of the sale, the chief operating officer now owns 2,389 shares of the company’s stock, valued at $323,828.95. This represents a 69.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

ICU Medical Stock Up 0.6%

Shares of ICU Medical stock opened at $141.38 on Friday. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. The company has a market cap of $3.48 billion, a P/E ratio of -30.94 and a beta of 0.87. The firm’s 50 day moving average price is $140.85 and its 200-day moving average price is $153.95. ICU Medical, Inc. has a 52-week low of $100.91 and a 52-week high of $196.26.

ICU Medical (NASDAQ:ICUIGet Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.49. The business had revenue of $599.49 million for the quarter, compared to analyst estimates of $574.15 million. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. The business’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.96 earnings per share. On average, sell-side analysts predict that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Woodline Partners LP boosted its holdings in ICU Medical by 31.6% in the first quarter. Woodline Partners LP now owns 160,910 shares of the medical instruments supplier’s stock worth $22,344,000 after acquiring an additional 38,671 shares in the last quarter. United Services Automobile Association purchased a new position in shares of ICU Medical in the 1st quarter valued at approximately $218,000. Dynamic Technology Lab Private Ltd boosted its stake in ICU Medical by 855.9% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 12,427 shares of the medical instruments supplier’s stock worth $1,726,000 after purchasing an additional 11,127 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in ICU Medical by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,764 shares of the medical instruments supplier’s stock worth $1,772,000 after purchasing an additional 560 shares in the last quarter. Finally, AQR Capital Management LLC grew its position in ICU Medical by 2.5% during the 1st quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier’s stock worth $1,297,000 after purchasing an additional 229 shares during the last quarter. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research note on Tuesday, April 8th. KeyCorp dropped their price objective on shares of ICU Medical from $209.00 to $191.00 and set an “overweight” rating on the stock in a research note on Monday, April 21st. Raymond James lowered their target price on ICU Medical from $197.00 to $187.00 and set a “strong-buy” rating for the company in a report on Friday, May 9th. Finally, StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a report on Sunday. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, ICU Medical presently has an average rating of “Buy” and an average price target of $192.67.

Get Our Latest Report on ICUI

ICU Medical Company Profile

(Get Free Report)

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

Featured Stories

Insider Buying and Selling by Quarter for ICU Medical (NASDAQ:ICUI)

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.